Quantcast

Latest Genzyme Stories

2014-08-18 12:26:52

DUBLIN, Aug. 18, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 The term lysosomal storage diseases refers to a group of rare inherited disorders caused by the deficiency of lysosomal enzymes, activator proteins, proteins required for normal post-translational modification of lysosomal enzymes or proteins required for intracellular...

2014-08-13 16:25:52

-- 2Q Revenue Increased 71%, Compared to Prior Year -- SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today reported financial results for the second quarter ended June 30, 2014, and provided an update on business progress. For the second quarter of 2014, revenue was $8.7 million, an increase of 71%, compared to $5.1 million for the second quarter of 2013. Revenue for the six months ended June 30, 2014 was $16.2 million, compared to $9.5 million for...

2014-07-31 04:22:57

PARIS, July 31, 2014 /PRNewswire/ -- Sanofi, a global and diversified healthcare leader, reports results for the first half of 2014. Chris Viehbacher, CEO of Sanofi, comments on results and outlook. Watch video interview and read transcript: http://eurobusinessmedia.com/ceo-direct/sanofi/interview-with-ceo-chris-viehbacher-h1-2014-results,2014-07-30,1235?utm_source=ceo-direct&utm_medium=wire Topics covered in the interview include:...

2014-07-03 12:26:08

STOCKHOLM, July 3, 2014 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, is very pleased to announce that Mrs Ann-Tove Kongsnes, Mrs Hilde Furberg and Mr Olav Hellebo were elected as new members of its Board of Directors at the Company's recent shareholders' meeting held in Stockholm. At the same meeting, Ms Elisabeth Lindner stepped down from the Board. Ann-Tove Kongsnes (born 1967) is an Investment Director at Investinor,...

2014-06-12 12:30:07

Current Neurologist-Reported Patient Share for Tecfidera Exceeds that of Genzyme's Aubagio and Novartis's Gilenya Combined, According to Findings from Decision Resources Group BURLINGTON, Mass., June 12, 2014 /PRNewswire/ -- Decision Resources Group finds that, within one year of commercial availability, 100 percent of surveyed U.S. neurologists have prescribed Biogen Idec's Tecfidera to at least one of their multiple sclerosis (MS) patients, far surpassing the one-year trial rate for...

2014-06-03 12:37:18

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Translational Regenerative Medicine: Market Prospects 2014-2024http://www.reportbuyer.com/pharma_healthcare/research_r_d/translational_regenerative_medicine_market_prospects_2012_2022.html Report DetailsOur new study shows you the commercial potential of regenerative treatmentsWhat does the future hold for regenerative medicine? Visiongain's brand new report shows you potential revenues to...

2014-05-15 12:29:33

LONDON, May 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Markets for Orphan Drugshttp://www.reportbuyer.com/pharma_healthcare/drug_discovery/global_markets_orphan_drugs.htmlINTRODUCTIONSTUDY OBJECTIVESThe orphan drug market is one of the fastest-growing segments in the pharmaceutical and biotechnology industry. BCC's goal in conducting this study is to provide an overview of the current and future global market for orphan drugs. The key...

2014-05-08 08:34:19

ROCKVILLE, Md., May 8, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced the appointment of Sandford Drexel Smith to its Board of Directors, bringing the total number of board members to seven, five of whom are independent. Mr. Smith is the former President, International Group, and Executive Vice President of Genzyme Corporation. He also served on Genzyme's Executive Committee, where he reported directly to the Chairman and CEO. As President of the International Group,...

2014-05-01 12:32:03

- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated with Lemtrada did not receive a third course of treatment in the first year of the extension - CAMBRIDGE, MA, May 1, 2014 /CNW/ - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced new magnetic resonance imaging (MRI) data from the Lemtrada (alemtuzumab) clinical development program. In Lemtrada...

2014-04-29 08:36:15

PARIS, April 29, 2014 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q1 2014 Change (reported) Change (CER) Net sales EUR7,842m -2.7% +3.5% Business net income(2) EUR1,547m -3.2% +5.6% Business EPS(1) EUR1.17 -3.3% +5.8% -------------- ------- ---- ---- In order to facilitate an understanding of our operational...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related